Ashwani Verma
Stock Analyst at UBS
(3.55)
# 930
Out of 5,044 analysts
91
Total ratings
52.24%
Success rate
5.97%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVDL Avadel Pharmaceuticals | Downgrades: Neutral | $20 | $18.59 | +7.58% | 4 | Oct 28, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $50 → $43 | $29.64 | +45.07% | 3 | Oct 15, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $188 → $195 | $147.38 | +32.31% | 10 | Oct 9, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $560 → $580 | $415.34 | +39.64% | 9 | Sep 29, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $23 → $26 | $19.78 | +31.45% | 10 | Sep 24, 2025 | |
| BHVN Biohaven | Maintains: Buy | $27 → $26 | $17.20 | +51.16% | 4 | Sep 16, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $36 → $39 | $22.62 | +72.41% | 7 | Sep 9, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $133 → $144 | $133.51 | +7.86% | 5 | Aug 6, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $43 → $38 | $40.08 | -5.18% | 4 | Jul 30, 2025 | |
| IMVT Immunovant | Maintains: Neutral | $17 → $18 | $21.98 | -18.11% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $32.57 | +65.80% | 3 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $33 → $42 | $31.00 | +35.48% | 5 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $61 | $91.65 | -33.44% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $47 → $41 | $61.97 | -33.84% | 5 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $1.74 | -39.66% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $179 | $138.13 | +29.59% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $87.49 | +30.30% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $36.41 | -23.10% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $134.24 | -94.79% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $10.29 | +16.62% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.89 | +693.65% | 1 | Oct 11, 2022 |
Avadel Pharmaceuticals
Oct 28, 2025
Downgrades: Neutral
Price Target: $20
Current: $18.59
Upside: +7.58%
Harmony Biosciences Holdings
Oct 15, 2025
Maintains: Buy
Price Target: $50 → $43
Current: $29.64
Upside: +45.07%
Neurocrine Biosciences
Oct 9, 2025
Maintains: Buy
Price Target: $188 → $195
Current: $147.38
Upside: +32.31%
United Therapeutics
Sep 29, 2025
Maintains: Buy
Price Target: $560 → $580
Current: $415.34
Upside: +39.64%
Teva Pharmaceutical Industries
Sep 24, 2025
Maintains: Buy
Price Target: $23 → $26
Current: $19.78
Upside: +31.45%
Biohaven
Sep 16, 2025
Maintains: Buy
Price Target: $27 → $26
Current: $17.20
Upside: +51.16%
ACADIA Pharmaceuticals
Sep 9, 2025
Maintains: Buy
Price Target: $36 → $39
Current: $22.62
Upside: +72.41%
Axsome Therapeutics
Aug 6, 2025
Maintains: Buy
Price Target: $133 → $144
Current: $133.51
Upside: +7.86%
Exelixis
Jul 30, 2025
Maintains: Neutral
Price Target: $43 → $38
Current: $40.08
Upside: -5.18%
Immunovant
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $21.98
Upside: -18.11%
Jul 2, 2025
Maintains: Buy
Price Target: $60 → $54
Current: $32.57
Upside: +65.80%
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $31.00
Upside: +35.48%
Jun 3, 2025
Maintains: Neutral
Price Target: $61
Current: $91.65
Upside: -33.44%
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $61.97
Upside: -33.84%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.74
Upside: -39.66%
Mar 7, 2025
Upgrades: Buy
Price Target: $145 → $179
Current: $138.13
Upside: +29.59%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $87.49
Upside: +30.30%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $36.41
Upside: -23.10%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $134.24
Upside: -94.79%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $10.29
Upside: +16.62%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $1.89
Upside: +693.65%